Vice Provost and Dean of Research
Showing 1-3 of 3 Results
Senior Associate Director, Licensing and Special Projects, Life Sciences, Office of Technology Licensing (OTL)
BioPrevious Work Experience:
Reche Corporation (Process Engineer)
Fairchild Semiconductor (Process Engineer)
Alza Corporation (Chemical Engineer)
Maxygen (Director, Business Development)
Biotechnology, Physical Sciences
Industrial Contracts Officer, Office of Technology Licensing (OTL)
BioIan Whyburn is an Industrial Contracts Officer in the Industrial Contracts Office at Stanford. He specializes in negotiating industry sponsored research agreements, material transfer agreements, collaboration agreements, and data use agreements, and advises faculty members, departmental research administrators, and partner organizations on all facets of sponsored projects. Before joining the Industrial Contracts Office, Ian worked in Stanford's Office of Sponsored Research where he drafted, reviewed, negotiated, and accepted contracts, grants, cooperative agreements, data use agreements, collaborative research agreements, subcontracts, and sub-awards with federal, non-profit, industry, and foreign sponsors.
Senior Technology Licensing and Strategic Alliances Manager, Office of Technology Licensing (OTL)
BioKathy joined the Stanford Office of Technology Licensing in 2022 as a Senior Technology Licensing & Strategic Alliances Manager. She has 8+ years of technology transfer experience at the University of California, San Francisco (UCSF), where she sourced and executed several high-value licenses and managed various industry collaborations. Kathy is passionate about working with faculty members and industry partners to forge novel paths for collaboration and licensing with the goal of bringing new technologies to the public domain. Prior to joining the technology transfer field, Kathy obtained a PhD in Genetics at Yale University and was a Postdoctoral Fellow at the Buck Institute for Research on Aging, where her research focused on the roles of histone deacetylase inhibitors and ribosomal proteins in breast cancer.